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Cord blood (CB) is either donated to public CB banks for use by any patient worldwide 
for whom it is a match or stored in a private bank for potential autologous or family 
use. It is a unique cell product that has potential for treating life-threatening diseases. 
The majority of CB products used today are for hematopoietic stem cell transplantation 
and are accessed from public banks. CB is still evolving as a hematopoietic stem cell 
source, developing as a source for cellular immunotherapy products, such as natural 
killer, dendritic, and T-cells, and fast emerging as a non-hematopoietic stem cell source 
in the field of regenerative medicine. This review explores the regulations, standards, 
and accreditation schemes that are currently available nationally and internationally for 
public and private CB banking. Currently, most of private banking is under regulated 
as compared to public banking. Regulations and standards were initially developed to 
address the public arena. Early responses from the medical field regarding private CB 
banking was that at the present time, because of insufficient scientific data to support 
autologous banking and given the difficulty of making an accurate estimate of the need 
for autologous transplantation, private storage of CB as “biological insurance” should be 
discouraged (1, 2, 3). To ensure success and the true realization of the full potential of 
CB, whether for autologous or allogeneic use, it is essential that each and every product 
provided for current and future treatments meets high-quality, international standards.
Keywords: cord blood, cord blood banking, standards, accreditation, regulations, autologous, altruistic, voluntary 
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inTRODUCTiOn
Following the first cord blood (CB) transplant for hematopoietic reconstitution (4), 27 years ago 
in France for a child with Fanconi Anemia, CB has moved rapidly from an experimental stem cell 
source to a widely accepted alternative to marrow as a source of hematopoietic stem cells. CB cur-
rently plays an important role in stem cell transplantation and cellular therapy, with an emerging role 
in regenerative medicine. CB transplantation is now a standard practice treatment option in both 
pediatric and adult transplantation for malignant and non-malignant disorders (5). CB has many 
advantages compared with other stem cell sources. From a safety perspective, it is a waste product; 
the collection process causes no harm to the donor infant and has a low risk of transmission of 
communicable diseases. Logistically, CB is an “off-the-shelf ” product; it can extend transplant access 
to more racial/ethnic minority patients, currently underrepresented on donor registries worldwide 
and through the increased level of human leukocyte antigen (HLA) disparity that can be tolerated.
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In the development of quality inventories, CB banks need to 
consider the critical issues for a high-quality CB unit to meet 
all current and potential clinical needs. The CB bank must take 
responsibility for providing first class products that are safe, pure, 
and potent. The CB unit being provided for clinical use may not 
only have been collected, tested, processed, and stored in a differ-
ent country but also may have been banked over two decades ago. 
The quality of the CB product and its ultimate effect in the recipi-
ent’s treatment is reliant on both the procedures and processes at 
that time of cryopreservation and the subsequent maintenance of 
proper storage conditions. By accepting a CB unit for clinical use, 
the clinical program accepts full responsibility that the product 
has been correctly processed and tested. Regulatory and accredi-
tation bodies, and registries have developed legislation, guidance, 
standards, and accreditation tools for CB banking. Compliance 
by the banks can provide clinical programs and the patients they 
treat the assurance that the CB unit not only has the correct 
HLA type and cell count but also contains viable hematopoietic 
progenitor cells that will result in durable engraftment or viable 
cellular immunotherapy products.
CORD BLOOD BAnKinG
A CB bank is a facility which stores umbilical CB for future use. 
Private and public CB banks have developed in response to this 
unique cell product with the potential for treating life-threatening 
diseases. There are also some, more recently emerging, hybrid CB 
banks providing both public and private storage.
 (a)  Public CB banks collect CB donations and store them 
indefinitely for possible clinical use. This unit is potentially 
available for any patient, if deemed a suitable HLA match. 
There is no charge to the donor, but the product is not stored 
specifically for that person or their family. These units are 
made available for search through national and international 
stem cell registries (6). Traditionally, public CB banking has 
been more widely accepted by the medical community (1, 
2). In the United States (US), there are currently 17 public 
banks. Funding for public CB banks comes from a variety of 
sources, such as government, institutional, and philanthropic 
grants and donations. However, for most banks, the revenue 
received from the issue of units for clinical use is used to 
underwrite the costs of banking and additional collections. 
Without national support, public CB donation will never be 
an option for every potential donor.
 (b)  Private CB banks provide CB storage to families for potential 
future autologous or family use. For this service, the banks 
charge an up-front collection fee and then typically charge 
a yearly rate for ongoing storage of the CB unit. Contrary 
to public banks, family banks are not subject to many of the 
regulations and international accreditation; so, they apply 
less stringent quality criteria for the storage of CB units. In 
the US, there are currently 36 private banks.
 (c)  Directed donor programs are offered by a number of private 
and public CB banks. This type of banking is solely for sibling 
donor collection for those families who are likely to consider 
CB transplantation because a first-degree relative has been 
diagnosed with a disease that is treatable with allogeneic CB 
transplantation (7). The rationale for these programs is that 
if the new baby’s HLA type is compatible with the affected 
sibling, CB has the potential to be a good source of cells 
for transplant for the donor’s sibling. The likelihood that a 
sibling will share both HLA haplotypes is 25%.
Not all CB collections are viable for use: some do not contain 
sufficient cells, some may be contaminated, and others may have 
poor viability. Ultimately, a large percentage of the collections 
for public banking are not stored for clinical use  –  at the MD 
Anderson Public CB Bank, 70% of collections do not meet the 
required criteria for banking. However, many of these unsuitable 
units are made available for research and development. Quality 
standards in private banks do not necessarily follow the same strict 
criteria, which may result in stored units not being fit for use, if 
needed. Many private banks advertise possible future uses that are 
not entirely supported by clinical evidence, such as a cure for heart 
disease or autism or as a panacea. Many parents are led to believe 
they are buying biological insurance for their child and may feel 
that peace of mind afforded by private storage is worth the price. 
Unfortunately, they are often misinformed and misled by inac-
curate information, vague promises, and aggressive marketing 
techniques that will exploit their feelings of guilt if they “miss this 
unique chance of saving their child’s life in the future” (3).
In the public CB banking arena, over 650,000 unrelated CB 
donations have been stored worldwide and listed on the Bone 
Marrow Donor’s Worldwide Registry (BMDW website: http://
www.bmdw.org). In family CB banking, it in unknown how many 
CB units have been stored; two of the largest family banks in the 
US, both indicate on their websites that they each have ~500,000 
units stored. More than 35,000 unrelated CB units have been dis-
tributed worldwide by public banks for allogeneic hematopoietic 
stem cell transplants, compared to <1,000 autologous transplants 
over the last two decades (8).
The role of a CB bank, public or private, is to assure patients and 
their families and their healthcare providers that they are com-
mitted to providing high-quality products that are potent, pure, 
and will not transfer an infectious, hematologic, or immunologic 
disease to the recipient. Regulations, standards, and accreditation 
in CB banking promote such assurance and continue to improve 
and progress the quality of the products for transplantation and 
cellular therapy treatments and develop regenerative medicine 
applications. It is paramount that all parties involved in collecting 
and supplying CB for clinical use work with the same goals and 
the same standards, including transplant outcome analysis as part 
of their quality management program.
CORD BAnKinG ReGULATiOnS
Many countries now regulate CB products.
 (a)  In the US, the Food and Drug Administration1 regulates CB 
under the category of Human Cells, Tissues, and Cellular 
1 http://www.fda.gov/
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and Tissue Based-Products (HCT/P), in line with the 21 
Code of the Federal Registry (9). Part 1271 and the Good 
Manufacturing Practices requirements in 21 CFR Parts 210 
and 211. All private and public banks are required to comply 
with the FDA requirements for establishment registration 
and listing, current Good Tissue Practice regulations and 
donor screening and testing for infectious diseases (except 
when CB is used for the original donor). The FDA periodi-
cally inspects both types of banks. Public CB banks are also 
required to obtain a Biological License as the FDA considers 
unrelated allogeneic CB products to have a systemic effect, 
and therefore they regulate them as biological products 
and drugs. After October 20, 2011, every unrelated donor 
CB unit transplanted in the US must be either licensed or 
covered under an FDA-accepted Investigational New Drug 
(IND) (10). CB stored for personal use, for use in first- or 
second-degree relatives, does not require the agency’s 
approval before use.
 (b)  The European Union (EU) regulates CB on quality and safety 
issues related to donation, procurement, testing, processing, 
preservation, storage, and distribution of human tissues and 
cells through the EU Directives 2006/17/EC and 2006/86/EC 
(11). In 2004, the Council of Europe Committee of Ministers 
recommended that
i. CB banking should be based on altruistic CB donation 
and used for allogeneic transplantation and related 
research;
ii. promotion and the establishment of CB banks for autolo-
gous use should not be supported by member states or 
their health services;
iii. where autologous CB banks are established, the promo-
tional material or information provided to families must 
be accurate, and fully informed consent to CB storage 
must be obtained;
iv. and autologous CB banks must meet the quality and 
safety standards set out in the Council of Europe’s Guide 
to safety and quality assurance for organs, tissues, and 
cells.
 (c)  Canada, Health Canada regulates CB under the Safety of 
Human Cells, Tissues and Organs for Transplantation, 
SOR/2007-118.
 (d)  The Australian Therapeutic Goods Administration (TGA) 
licenses CB through the Therapeutic Goods Act 1989 (12). 
Applying a risk management approach designed to ensure 
therapeutic goods supplied in Australia meet acceptable 
standards of quality, safety, and efficacy.
The similarity throughout these regulations is compliance 
with Good Manufacturing Practices to produce a safe and effec-
tive product for its intended use.
CORD BLOOD BAnKinG STAnDARDS
Cord blood standards are designed to provide minimum guide-
lines for all aspects of the CB bank’s operations, consistently 
assuring provision of quality products while protecting research, 
development, and new products. Standards are not intended to 
establish best practices or include all procedures that a CB bank 
should implement, if the standard of practice in applicable law 
establishes additional requirements. Compliance with standards 
is not an exclusive means of complying with the standard of care 
in the industry or with local, national, or international laws. It is 
critical that standards for CB banking be international, since CB 
products frequently cross international borders. The best CB unit, 
selected by HLA type and cell dose, is often located in another 
country. Transport across borders requires compliance with 
the regulations of the donor country and the receiving country. 
Both the AABB (formerly known as the American Association 
of Blood Banks) and the Foundation for the Accreditation of 
Cellular Therapy2 together with NetCord (NetCord-FACT) have 
developed international standards for CB banking quality man-
agement systems and technical requirements that both private 
and public banks may elect to follow for both unrelated and 
related products. The AABB standards for CB banks are incor-
porated into their cellular therapy standards and FACT-NetCord 
publish separate CB standards, aligned with their cellular therapy 
standards but unique to CB banking.
Standards are developed by consensus, based on the best avail-
able evidence-based science, with emphasis on research findings 
related to clinical outcome from CB recipients. When published 
data are not available, requirements are based upon accepted 
scientific theory. Standards are written by invited international 
leaders in cellular therapy programs and CB banks: knowledge-
able clinicians, scientists, technologists, and quality experts that 
span the entire continuum of CB banking. Liaison representation 
from consumers and regulatory bodies are consulted throughout 
the development process to ensure detailed, comprehensive 
standards that address each aspect of a CB bank’s operations 
whether public or private:
 (a)  procurement of CB, regardless of technique or type of collec-
tion site;
 (b)  donor screening, testing, eligibility determination of the 
mother and donor infant, in accordance with applicable law;
 (c)  processing, cryopreservation and storage, including quaran-
tine, testing and characterization of the product;
 (d)  making the product available for search, if unrelated;
 (e)  search and reservation process for selection of a specific unit;
 (f)  shipment of the CB unit, whether fresh or cryopreserved;
 (g)  release and distribution, including release testing to confirm 
product viability and hematopoietic potential.
The development process includes a period for public and 
professional review and comment, legal review, and approval 
by the relevant Board of Directors prior to publication of a new 
edition of the standards. The standards do not dictate how to meet 
a requirement and, even though they are international standards, 
it is not their intent to include every requirement of every govern-
ment’s regulations. CB banking is a fast-evolving field and the 
standards need to evolve dynamically – both sets of standards are 
reviewed and revised on a defined periodic basis, with the option 
2 http://www.factwebsite.org/
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to publish interim standards based on changes to applicable laws 
and regulations, field experience, or misinterpretations.
In addition to the standards, an accreditation manual is devel-
oped simultaneously to provide guidance to applicants and to the 
on-site inspectors. This manual is intended to explain the intent 
and rationale for specific standards and to provide explanations, 
examples, and alternative approaches that may be helpful in the 
accreditation process. This is not an exhaustive list of possible 
ways to meet the standards, and the only intent is to provide 
examples since there are many effective mechanisms to achieve 
compliance with the standards and to inspect applicant CB Banks.
The NetCord-FACT Standards apply to CB units intended 
for unrelated use and to related units, collected, and stored for 
the directed use by a specific individual or family member of the 
donor infant. In previous editions, the standards distinguished 
between directed allogeneic and autologous units; since the 
ultimate use of a unit stored for family use is often unknown at 
time of storage, the concept of related replaces the terms directed 
allogeneic and autologous.
To be compliant with the both sets of standards, a CB bank is 
required to maintain a documented quality management program 
and use validated procedures and qualified supplies, reagents, and 
equipment. In addition, the NetCord-FACT standards require the 
tracking of clinical outcomes of patients receiving products from 
the bank.
ACCReDiTATiOn
The basis for accreditation is to show documented compliance 
with the current edition of the standards. Accreditation establishes 
a uniform level of practice and promotes high-quality products/
practices, leading to improved patient outcomes and elevates the 
bank’s position as a quality organization and informs patients, 
health insurance companies, and governments that your organi-
zation is dedicated to excellence in patient care and laboratory 
practices. Accreditation provides evidence of external validation 
through on-site inspections and facilitates the establishment of 
quality management and process control to minimize liabilities 
and regulatory non-compliance. Accredited organizations volun-
tarily seek and maintain accreditation through a rigorous process, 
demonstrating their belief that the patients’ needs are paramount.
All FACT-NetCord inspectors are expert volunteers, trained 
and active in the field; generally, three inspectors spend two full 
days at the facility to observe and review. Forty-six public CB 
banks and seven private CB banks are FACT-NetCord accredited 
(see footnote text 2), and a total of 69 CB banks, private and 
public, are AABB accredited,3 as of September 2015.
Any CB bank that lists their units on the NMDP registry 
are required to be either FACT-NetCord or AABB accredited. 
NetCord member banks are required to hold FACT accreditation. 
The Spanish National CB Program requires all CB units listed in 
the Spanish Registry REDMO to be accredited either by FACT-
NetCord or by the Spanish CAT (Transfusion Accreditation 
Committee), responsible for inspecting blood banks in Spain. 
Several US states also require accreditation, including New York, 
New Jersey, and California. Any bank not accredited within those 
states is not legally permitted to collect CB from those states, even 
if the CB bank is based out of state.
COnCLUSiOn
A public donation is made as a purely altruistic act, solely for 
the benefit of others. It has the potential to save the life of any 
person for whom the unit is a good match, including the person 
who donated it, if it is still available. Private CB banks store a unit 
solely for use by the donor or their family. However, the US, as in 
many countries, does not have an organized public CB banking 
system; in most of the country, public donation is not even pos-
sible – almost 90% of CB in the US are not collected. So for many 
people, the choice is not between public and private banking, it is 
between private banking and letting the CB go to waste.
Increasing evidence shows CB contains pluripotent stem cells 
that have the potential to differentiate into non-hematopoietic 
tissue, such as cardiac, neurologic, pancreatic, and skin tissue. 
Extensive laboratory research is taking place to explore the 
potential therapeutic benefit of CB under these circumstances. 
The results of this research will be necessary to formulate future 
recommendations regarding autologous CB banking.
Cord blood, whether donated for public banking or stored at 
the request of a family, is a unique cell product. To ensure success 
and the true realization of the full potential of CB now and in 
the future, whether for autologous or allogeneic use, it is essential 
that each and every product provided for current and future treat-
ments meets high-quality defined international standards. The CB 
industry, private and public banks, stakeholders, and consumers 
must work together to develop thriving CB banking opportuni-
ties, producing high-quality CB products to improve outcome.
3 http://www.aabb.org/
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